MLR review is the medical, legal, and regulatory review that a pharmaceutical, biotech, or medical device company runs on a piece of material before anyone outside the company sees it. A reviewer from each of the three functions reads the same draft, checks it against what their function is responsible for, and signs off. Until all three have approved it, the material is not used. The term covers promotional pieces such as sales aids, emails, and speaker decks, and at many companies a version of the same review covers educational and medical materials too.
Quick answer: MLR stands for medical, legal, and regulatory. Medical checks that every claim is scientifically accurate and supported by a cited source. Legal checks the piece for liability, comparative claims, trademarks, and anything that could look like an inducement. Regulatory checks that it matches the approved label, presents benefit and risk in fair balance, and meets FDA submission rules. The review decides whether a specific piece can be used. It does not decide strategy, who attends a program, or what an HCP is paid.
Why companies run MLR review
No FDA regulation uses the term MLR. Companies built the process to meet obligations that do exist. Under 21 CFR 314.81(b)(3)(i), a drug sponsor has to submit its promotional labeling and advertising to FDA at the time the piece is first disseminated or published, with a completed Form FDA-2253 and a copy of the current prescribing information. FDA's prescription drug advertising rules say an ad is not a true statement if it gives effectiveness more scope, depth, or detail than side effects and contraindications. The Office of Prescription Drug Promotion reviews what companies submit and can act on what it finds.
Because the submission happens at first use, FDA usually sees a piece after it is already in circulation. MLR review is how a company catches problems before that point. It also gives the company a dated record of who approved which version, which matters when a piece is questioned months later.
Who sits on the review
The core team is one reviewer from each function. Many companies add a compliance reviewer, and the person who wrote or commissioned the piece usually submits it and answers comments. Some call the group a promotional review committee. The work each reviewer does looks like this:
| Reviewer | Question they answer | What they usually send back |
|---|---|---|
| Medical | Is every claim accurate, and does the cited source actually support it? | A reference that says less than the claim, a subgroup result shown as the main finding, a chart with the axis cut |
| Legal | Could this create liability or look like an inducement? | Comparative claims without head-to-head data, trademark use, offers tied to prescribing |
| Regulatory | Is this consistent with the approved label and FDA's rules for the channel? | Off-label implications, missing or buried safety information, a 2253 submission not planned |
What the review looks at
The reviewers read the whole piece, including the footnotes. A typical submission arrives with each claim annotated to the page and line of its reference, so the medical reviewer can check the source rather than trust the summary. Reviewers also look at the intended audience and channel, because a statement that is fine in a slide for specialists may not be fine in a patient email.
Most comments fall into a few groups. Claims go further than the data. Risk information is smaller, later, or harder to find than the benefit. Wording suggests a use the label does not include. Images imply something the text does not say. The submitter revises, and the piece goes back around until each reviewer approves the same final version.
Approval is not permanent. Companies set an expiry or a re-review date, and a label change, new safety data, or a new indication usually sends every affected piece back through review. Pieces that are withdrawn should stop being used everywhere, including in the field.
What MLR review does not decide
MLR approves a piece of content. It does not decide whether a campaign or a program should exist, which HCPs are invited, who is chosen to speak, or what a speaker is paid. Those decisions sit with brand, medical, and compliance owners under the company's other policies. It also does not script a live conversation. When an HCP asks an MSL an unsolicited question about an unapproved use, the answer comes from the medical information process, not from an approved promotional piece.
Medical affairs materials sit at the edge of the process. Slide decks an MSL uses in scientific exchange, scientific response documents, and congress materials are non-promotional, so many companies send them through a separate medical review with different reviewers and rules. The point of keeping them apart is that a piece built to answer a scientific question should not be shaped by promotional goals.
Where a reviewed piece is used
A speaker program is the clearest case. The deck goes through MLR review, the speaker is trained on it, and the speaker presents that version without changes. Months later, someone may need to show which deck was used at which event. In TikaSpeaker Bureau, the agenda, slides, and materials sit on each company-run program with their versions, so the deck shown at an event can be matched to the version that was approved. The review itself happens in the company's own review system.
Frequently asked questions
What does MLR stand for in pharma?
MLR stands for medical, legal, and regulatory. It is the review in which reviewers from those three functions check promotional and other external materials before a pharmaceutical, biotech, or medical device company uses them.
Who sits on an MLR review committee?
At minimum, one reviewer each from medical, legal, and regulatory. Many companies add a compliance reviewer, and the person who created or commissioned the material submits it and responds to comments.
Is MLR review required by FDA?
No FDA regulation uses the term. Companies run MLR review to meet requirements that do exist, including fair balance in prescription drug advertising under 21 CFR 202.1 and the submission of promotional materials to FDA on Form 2253 at first use under 21 CFR 314.81(b)(3)(i).
Do medical affairs materials go through MLR review?
It depends on the company. Promotional materials go through MLR review. Non-promotional materials such as MSL slide decks, scientific response documents, and congress materials are often reviewed through a separate medical review process with its own reviewers and rules.
If your team runs company programs and needs to show which approved deck was used at each one, we can walk through how the program, the speaker, and the materials sit on one record.
Book a 20-minute walkthrough →
Sources
- Code of Federal Regulations. 21 CFR 314.81, Other postmarketing reports, paragraph (b)(3)(i), Advertisements and promotional labeling.
- Code of Federal Regulations. 21 CFR 202.1, Prescription-drug advertisements, paragraph (e)(5).
- U.S. Food and Drug Administration. Office of Prescription Drug Promotion (OPDP).
Glossary
November 1, 2026
